Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Nurix Therapeutics, Inc.
| Metric | Nurix Therapeutics, Inc. NRIXHealthcare |
|---|---|
| Quality Score | 55 / 100 |
| Revenue (latest) | $84M |
| Net income (latest) | −$264M |
| Operating margin | −340.2% |
| Net margin | −314.9% |
| Return on equity | −49.1% |
| Return on assets | −38.4% |
| Return on capital (ROCE) | −47.5% |
| Debt / equity | 0.28× |
| Revenue growth (YoY) | 54.0% |
| Altman Z″ (distress) | 1.20 |
| Accruals / assets | −2.2% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.